Mbiomics focuses on developing the first generation of effective bacterial live therapeutics. The company uses its proprietary profiling platform and computational technologies to generate high-resolution precision data for microbiota modulation. The technology is designed to enable a better understanding of the interactions between the gut microbiome and the host, allowing Mbiomics to develop microbial consortia that can be provided to patients as precision therapies. The Munich biotech company aims to revolutionize the treatment of a broad spectrum of diseases – from cancer to inflammatory bowel diseases.
“Harnessing the power of the microbiome to treat diseases”
Markus Rinecker, co-founder and CMO of Mbiomics, comments:
“The microbiome offers a rich source of new therapeutic possibilities that have not yet been fully explored. Our goal is to harness the power of the microbiome to treat diseases that are difficult to manage with conventional approaches. Our excellent R&D team has delivered a technological proof-of-concept for our analysis platform in record time. With this technology, Mbiomics is in a unique position to understand microbiome modulation and develop effective therapies.”
Laura Figulla, co-founder and CEO of Mbiomics, adds:
“We are very pleased by the support of such a renowned group of investors who share our vision of leveraging the potential of the gut microbiome to develop targeted therapies. This financing allows us to build out our platform, accelerate the selection of our first leading product candidates, and intensify research activities with a view to clinical validation.”
“Great potential”
“The influence of the microbiome on diseases is currently being researched in many ways”,
says Monika Steger, managing director of Bayern Kapital.
“Mbiomics demonstrates great potential in the development of microbiome-based therapeutics for supportive intervention in various diseases and can thus advance research by a decisive step. We look forward to walking this path together with the company and an experienced and financially strong investor consortium.”
And Jan Engels, investment manager at High-Tech Gründerfonds, adds:
“In the development of ‘live bacterial products’, the creation of microbiome profiles remains one of the greatest challenges. Mbiomics has developed a novel high-performance profiling platform that addresses the key bottlenecks in developing microbiome-based therapeutic approaches using novel bacterial consortia. We are pleased to invest together with strong co-investors in an outstanding team and innovative technology”,
